If Phase 1 trials go well and 191 turns out to be anywhere near as potent as preclinical data suggests might Roche first try a lot lower dose of 1626 before trying another Polymerase?
the efficacy standard vertex is setting would seem to place combination therapy earlier in the developmental timetable for competitors, and the roche-intermune collaboration would have been a natural fit for just this. I wonder if vrtx will partner with someone, who it will be, and when?
Market Data 
Markets 
AI
